Building on a suite of development candidate antibiotics from IMB, we combine some of Australia’s best minds in drug design and discovery to fast-track development of new antibiotics. More than $20 million of research grants has formed the backbone of an aggressive lead optimisation program to progress candidate antibiotics that can combat superbug infections.

Impacts and applications
A new antibiotic to treat MRSA (Golden Staph), S. pneumoniae, and C. difficile is at a commercialisation stage, with other research programs focused on innovative new approaches to treat tuberculosis and serious Gram-negative ‘ESKAPE’ human pathogens.

Project members

Key contact

Associate Professor Mark Blaskovich

Director, IMB Centre for Superbug Solutions
Principal Research Fellow - GL
Institute for Molecular Bioscience